MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 48 filers reported holding MERSANA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $2,395,000 | +42.9% | 90,000 | 0.0% | 0.02% | +18.8% |
| Q3 2020 | $1,676,000 | -20.4% | 90,000 | 0.0% | 0.02% | -27.3% |
| Q2 2020 | $2,106,000 | +222.5% | 90,000 | -78.2% | 0.02% | +214.3% |
| Q3 2019 | $653,000 | -93.5% | 413,525 | -83.2% | 0.01% | -92.7% |
| Q2 2019 | $9,981,000 | -41.0% | 2,464,415 | -23.4% | 0.10% | -39.6% |
| Q1 2019 | $16,916,000 | +104.5% | 3,216,002 | +58.6% | 0.16% | +82.8% |
| Q4 2018 | $8,272,000 | -55.1% | 2,027,505 | +10.2% | 0.09% | -43.5% |
| Q3 2018 | $18,403,000 | -17.6% | 1,840,333 | +47.1% | 0.15% | -24.9% |
| Q2 2018 | $22,342,000 | +51.9% | 1,250,977 | +34.2% | 0.20% | +39.5% |
| Q1 2018 | $14,704,000 | -0.5% | 932,396 | +3.6% | 0.15% | -2.0% |
| Q4 2017 | $14,783,000 | +79.0% | 899,773 | +88.4% | 0.15% | +59.6% |
| Q3 2017 | $8,260,000 | +68.9% | 477,711 | +36.5% | 0.09% | +54.1% |
| Q2 2017 | $4,890,000 | – | 350,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $4,896,124 | 6.42% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $35,608 | 4.45% |
| Sarissa Capital Management LP | 3,800,000 | $15,618,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $3,716,541 | 1.50% |
| 5AM Venture Management, LLC | 1,185,000 | $4,870,350 | 1.24% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 540,059 | $2,219,642 | 0.92% |
| Orbimed Advisors | 9,011,437 | $37,037,006 | 0.73% |
| Lion Point Capital, LP | 409,120 | $1,681,483 | 0.69% |
| DAFNA Capital Management LLC | 510,863 | $2,099,647 | 0.63% |
| Artal Group S.A. | 2,215,788 | $9,107 | 0.54% |